Cargando…
Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma
Background: Targeted therapy of Neurofibromatosis type 1 (NF1) related plexiform neurofibroma (pNF) aiming at MEK molecule has not demonstrated a convincing result for complete disease inhibition, probably due to other signal pathways crosstalk. Our previous study revealed an increased nuclear trans...
Autores principales: | Tian, Zhuowei, You, Yuanhe, Xiao, Meng, Liu, Jialiang, Xu, Guisong, Ma, Chunyue, Du, Zhong, Wang, Yanan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812799/ https://www.ncbi.nlm.nih.gov/pubmed/36619222 http://dx.doi.org/10.7150/ijms.78386 |
Ejemplares similares
-
Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study
por: Suenobu, Souichi, et al.
Publicado: (2023) -
Plexiform Neurofibroma in the Axilla with Intraosseous Neurofibroma in the Humerus in Neurofibromatosis 5
por: Khaladkar, Sanjay Mhalasakant, et al.
Publicado: (2018) -
Acneiform rash as a side effect of selumetinib in a child with neurofibromatosis type 1 treated for inoperable plexiform neurofibromas: Good results with doxycycline
por: Volontè, Martina, et al.
Publicado: (2022) -
Congenital Craniofacial Plexiform Neurofibroma in Neurofibromatosis Type 1
por: Cacchione, Antonella, et al.
Publicado: (2021) -
Giant Pelvic Neurofibroma in Patient with Plexiform Sciatic Neurofibroma and Neurofibromatosis Type 1
por: Temelkova, Ivanka, et al.
Publicado: (2019)